Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06002971 · ClinicalTrials.gov registry record
CONNEQT Pulse Validation Study
A clinical trial, sponsored by Mount Carmel Health System.
- Terminated
- Registry status
- 41
- Enrollment target
NCT06002971: Clinical Trial study, sponsored by Mount Carmel Health System.
NCT06002971 is a clinical trial that was terminated before completion, run by Mount Carmel Health System. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06002971 was terminated before completion, sponsored by Mount Carmel Health System.
- TERMINATED
- Registry status
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to validate the accuracy of the CONNEQT Pulse blood pressure monitoring system for the measurement of blood pressure as compared to a gold standard, auscultatory sphygmomanometer in a pregnant population.
Primary Outcome
Paired means and standard deviations of both systolic and diastolic blood pressure readings will be analyzed according to section 5.2.4.1.2 of ISO 81060-2 protocol.
Interventions
- DEVICE Blood pressure measurement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-08-21 |
| Est. Completion | 2025-06-03 |
Why NCT06002971 stopped before completion
NCT06002971 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 41 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood pressure measurement is the first listed.
NCT06002971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06002971 about?
NCT06002971 is a clinical study titled "CONNEQT Pulse Validation Study". The purpose of this study is to validate the accuracy of the CONNEQT Pulse blood pressure monitoring system for the measurement of blood pressure as compared to a gold standard, auscultatory sphygmomanometer in a pregnant population.
What is the current status of trial NCT06002971?
This trial is currently terminated. The enrollment target is 41 participants. The study started on 2023-08-21. Estimated completion is 2025-06-03.
What interventions are being tested in trial NCT06002971?
The interventions under investigation include: Blood pressure measurement (DEVICE).
Who is sponsoring clinical trial NCT06002971?
This trial is sponsored by Mount Carmel Health System, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI